McGowan factor

The McGowan factor has now been virtually replaced by measurement of the following properties of the effluent ... 

Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-betal correlates with long-term renoprotection in insulin-dependent diabetic patients. American Journal of Kidney Diseases 1999, 34, 818-823. 

Islam M, Burke JF, Jr., McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001 59 498-506. 

Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnilc BR, et al. Increased renal production of transforming growth factor-betal in patients with type II diabetes. Diabetes 1997 46 854-9. 

Rush, R.A., Williams, R., Wilson, P.A., Vahaviolos, J. and McGowan, R. (1989) Histological identification of nerve growth factor and its mRNA. In R.A. Rush (Ed.), Nerve Growth Factors, Wiley, Chichester, pp. 171-190. 

McGowan states that the factor of 19 does not apply to strained systems, but gives no indication of how such difficulties are overcome. Nevertheless, he quotes values for aromatics, although they have obviously not been obtained from the simple scheme outlined above. 

Mullen MP, Wessel DL, Thomas KC, Gauvreau K, Neufeld EJ, McGowan Jr. FX, Dinardo JA. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 2008 107(2) 371-8. 

McGowan, J. 1952a. The physical toxicity of chemicals, II. Factors affecting physical toxicity in aqueous solutions. J. Appl. Chem. 2 323-328. 

---